• Journal of Hospice and Palliative Care
• /
• v.17 no.4
• /
• pp.207-215
• /
• 2014

Multiple bone metastases are common manifestation of many malignant tumors such as lung cancer, breast cancer, prostate cancer and renal cell carcinoma. Bone metastasis is secondary cancer in the bone, and it can lead to bone pain, fracture, and instability of the weight bearing bones, all of which may profoundly reduce physical activity and life quality. Treatment for bone metastasis is determined by multiple factors including pathology, performance status, involved site, and neurologic status. Treatment strategies for bone metastasis are analgesics, surgery, chemotherapy and radiotherapy. External beam radiotherapy has traditionally been an effective palliative treatment for localized painful bone metastasis. However, in some cases such as multiple bone metastases, especially osteoblastic bone metastasis originated from breast or prostate cancer, the radiopharmaceutical therapy using $^{89}Sr$, $^{186}Re$, $^{188}Re$, $^{153}Sm$ and $^{117m}Sn$ are also useful treatment option because of administrative simplicity (injection), few side effects, low risk of radiation exposure and high response rate. This article offers a concise explanation of the radiopharmaceutical therapy for multiple bone metastases.

• 대한핵의학회:학술대회논문집
• /
• 1999.11a
• /
• pp.23.1-23.1
• /
• 1999

• 대한핵의학회:학술대회논문집
• /
• 2004.11a
• /
• pp.396.2-396.2
• /
• 2004

• Proceedings of the Korean Nuclear Society Conference
• /
• 2001.05a
• /
• pp.435-435
• /
• 2001

• 대한핵의학회:학술대회논문집
• /
• 2001.11a
• /
• pp.34.2-34.2
• /
• 2001

• 대한핵의학회:학술대회논문집
• /
• 1998.11a
• /
• pp.23.2-23.2
• /
• 1998

• Journal of Radiation Protection and Research
• /
• v.25 no.4
• /
• pp.191-195
• /
• 2000

This study was undertaken to estimate the exposed dose of the medical personnel during the intracoronary radiotherapy procedure as a part of ongoing SPARE (Seoul National University Hospital Post-Angioplasty Rhenium) trial. Data of thirty-four patients among forty-two irradiated patients participating in this trial due to coronary artery stenosis were retrospectively analyzed. Intracoronary radiotherapy was delivered to the patient immediately after angioplasty ballooning. Prescribed dose was 17 Gy to media of the diseased artery and was delivered with $^{188}Re$ filled balloon catheter. Dosimetry was carried out with GM counter at eight different points. Ten centimeter and forty centimeter from the patient's heart were selected to represent maximum and whole-body exposed dose of the operator, respectively. Median delivered dose was 111.6 mCi with average treatment time of 576 seconds. Average exposed dose rate at 10 cm and 40 cm from the patient's heart were 0.43 mSv/hr and 0.30 mSv/hr, respectively. Average exposed doses per treatment were 0.07 mSv and 0.05 mSv for 10 cm and 40 cm from the patient's heart, respectively. Exposed doses measured are much lower than recommended limit of 50 mSv for radiation workers or 1 mSv for general population in ICRP-60. This study proves that current method of intracoronary radiotherapy incorporated in this trial is very safe regarding radiation protection.

• The KIPS Transactions:PartA
• /
• v.8A no.2
• /
• pp.179-188
• /
• 2001

We analyze the property of candidate node set in the network graph, and propose an algorithm to decrease shortest path-finding computation time by using multiple dynamic-range queue(MDRQ) structure. This MDRQ structure is newly created for effective management of the candidate node set. The MDRQ algorithm is the shortest path-finding algorithm that varies range and size of queue to be used in managing candidate node set, in considering the properties that distribution of candidate node set is constant and size of candidate node set rapidly change. This algorithm belongs to label-correcting algorithm class. Nevertheless, because re-entering of candidate node can be decreased, the shortest path-finding computation time is noticeably decreased. Through the experiment, the MDRQ algorithm is same or superior to the other label-correcting algorithms in the graph which re-entering of candidate node didn’t frequently happened. Moreover the MDRQ algorithm is superior to the other label-correcting algorithms and is about 20 percent superior to the other label-setting algorithms in the graph which re-entering of candidate node frequently happened.

• Radiation Oncology Journal
• /
• v.30 no.4
• /
• pp.182-188
• /
• 2012

Purpose: For recurrent esophageal cancer after primary definitive radiotherapy, no general treatment guidelines are available. We evaluated the toxicities and clinical outcomes of re-irradiation (re-RT) for recurrent esophageal cancer. Materials and Methods: We analyzed 10 patients with recurrent esophageal cancer treated with re-RT after primary definitive radiotherapy. The median time interval between primary radiotherapy and re-RT was 15.6 months (range, 4.8 to 36.4 months). The total dose of primary radiotherapy was a median of 50.4 Gy (range, 50.4 to 63.0 Gy). The total dose of re-RT was a median of 46.5 Gy (range, 44.0 to 50.4 Gy). Results: The median follow-up period was 4.9 months (range, 2.6 to 11.4 months). The tumor response at 3 months after the end of re-RT was complete response (n = 2), partial response (n = 1), stable disease (n = 2), and progressive disease (n = 5). Grade 5 tracheoesophageal fistula developed in three patients. The time interval between primary radiotherapy and re-RT was less than 12 months in two of these three patients. Late toxicities included grade 1 dysphagia (n = 1). Conclusion: Re-RT of recurrent esophageal cancer after primary radiotherapy can cause severe toxicity.

• Nuclear Engineering and Technology
• /
• v.55 no.5
• /
• pp.1871-1877
• /
• 2023

The main goal of the coordinated project development of therapeutic radiopharmaceuticals of Y-90 and Re-188 is to exploit advancements in radionuclide production technology. Here, direct and indirect production methods with medium reactor and cyclotron are compared to evaluate derived neutron flux and production yield. First, nano-sized ¹⁸⁶W and ⁸⁹Y specimens are suspended in water in a quartz vial by FLUKA simulation. Then, the solution is irradiated for 4 days under 9E+14 n/cm2/s neutron flux of reactor. Also, a neutron activator including three layers-lead moderator, graphite reflector, and polyethylene absorbent- is simulated and tungsten target is irradiated by 60 MeV protons of cyclotron to generate induced neutrons for ¹⁸⁸W and ⁹⁰Sr production via neutron capture. As the neutron energy reduced, the flux gradually increased towards epithermal range to satisfy (n/2n,γ) reactions. The obtained specific activities at saturation were higher than the reported experimental values because the accumulated epithermal flux and nano-sized specimens influence the outcomes. The beta emitters, which are widely utilized in brachytherapy, appeal an alternative route to locally achieve a rational yield. Therefore, the proposed method via neutron activator may ascertain these broad requirements.